Drug intelligence / Profile preview

ST-067 + teclistamab

Development stage: Unknown
Lead developer: Simcha Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

ST-067 + teclistamab is a combination therapy being developed by Simcha Therapeutics for the treatment of multiple myeloma. ST-067 is an engineered, decoy-resistant interleukin-18 (IL-18) cytokine designed to bypass the inhibitory effects of IL-18 binding protein (IL-18BP), thereby enhancing the activation and expansion of T cells and natural killer (NK) cells. Teclistamab (Tecvayli) is a bispecific T-cell engager (BiTE) that targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, facilitating T-cell-mediated lysis of the tumor cells. The combination aims to leverage the immunostimulatory properties of IL-18 to potentiate the anti-tumor activity of the T-cell engager.

Brand names: Tecvayli
Other names: ST-067 + Tecvayli

Targets

IL-18R (Interleukin-18 receptor complex)IL18BP (Interleukin-18 binding protein)BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on ST-067 + teclistamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-067 + teclistamab.

Explore the full profile